Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)

ClinicalTrials.gov ID: NCT01421498

Public ClinicalTrials.gov record NCT01421498. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 10:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double- Masked and Placebo-Controlled Study Evaluating the Efficacy of a 5.0% Concentration of SAR 1118 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (OPUS-1)

Study identification

NCT ID
NCT01421498
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Shire
Industry
Enrollment
588 participants

Conditions and interventions

Interventions

  • Lifitegrast Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 28, 2011
Primary completion
Apr 27, 2012
Completion
Apr 27, 2012
Last update posted
Jun 10, 2021

2011 – 2012

United States locations

U.S. sites
13
U.S. states
7
U.S. cities
13
Facility City State ZIP Site status
OPUS-1 Investigational Site Waterbury Connecticut 06708
OPUS-1 Investigational Site Louisville Kentucky 40405
OPUS-1 Investigational Site Augusta Maine 04330
OPUS-1 Investigational Site Lewiston Maine 04243
OPUS-1 Investigational Site Andover Massachusetts 01840
OPUS-1 Investigational Site Lancaster Massachusetts 01523
OPUS-1 Investigational Site Quincy Massachusetts 02169
OPUS-1 Investigational Site Wakefield Massachusetts 01880
OPUS-1 Investigational Site Winchester Massachusetts 01890
OPUS-1 Investigational Site Derry New Hampshire 03038
OPUS-1 Investigational Site Manchester New Hampshire 03101
OPUS-1 Investigational Site Memphis Tennessee 38119
OPUS-1 Investigational Site Norfolk Virginia 23502

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01421498, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 10, 2021 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01421498 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →